Drug Trial Radar · NCT06987058
RVU120 Rollover Study
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
14
Planned (sponsor's estimate)
Start
Dec 4, 2025
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Ryvu Therapeutics SAIndustry
- Sponsor type
- Industry
- First posted
- May 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter rollover study to provide continued treatment to eligible participants previously enrolled in a RVU120 clinical study and to evaluate the safety of the treatment and record the time on treatment when continued under the same regimen as in the parent study. To be eligible for this rollover study, participants must be continuing to benefit from their treatment, show an acceptable safety profile, and not have access to commercially available comparator anticancer therapy. Once transitioned to this study, participants will continue with their next planned dose per the regimen of their parent study.
Conditions
- Advanced Solid Tumors
- Acute Myeloid Leukaemia (AML)
- High-risk Myelodysplastic Syndrome
Interventions
RVU120Drug
RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
RuxolitinibDrug
Selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (Safety and Tolerability)Time frame: 12 months
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Hôpital l'Archet 1 - CHU de Nice; Service Hématologie Clinique
Nice, France
Hôpital Haut-Lévêque- CHU de Bordeaux, Centre François Magendie, Service d'Hématologie Clinique et Thérapie Cellulaire
Pessac, France
M2M Med Sp. Z o.o.
Chorzów, Poland
CWBK UCK Ośrodek Badań Klinicznych Wczesnych Faz
Gdansk, Poland
Pratia Hematologia Sp. z o.o. Pratia Onkologia Katowice
Katowice, Poland
SPZOZ Szpital Uniwersytecki w Krakowie
Krakow, Poland
Uniwersytecki Szpital Kliniczny-Klinika Hematologii, Terapii Komórkowych i Chorób Wewnętrznych
Wroclaw, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.